Omega-3, Nigella Sativa, Indian Costus, Quinine, Anise Seed, Deglycyrrhizinated Licorice, Artemisinin, Febrifugine on Immunity of Patients With (COVID-19)

• Status: Recruiting
• Trial end date: 2020-12-04
• Target enrollment: 0
• Participant gender: All

Summary

The first version of this preprint article is registered on the 4th of May 2020 under the digital object identifier of:10.31219/osf.io/u56fc.

COVID-19 infections virus spread worldwide and impact many countries with sever economical sequences. The effective antiviral medication or vaccination for the virus is unavailable until the present date and it takes months or years to discover the effective treatment or test the efficacy of the discovered treatment.

Based on these facts, the human immune system against the virus may have an effective role to regulate the infection and reduce the mortality rate among the infected patients. This proposed research article aims to explore the available medication/ natural supplementation to boost the immunity system of the patients against COVID-19 infections and reduce the mortality rate among infected patients. Methods: a proposed clinical trial will be carried out to investigate the effect of the different treatment modalities on the human immune system against COVID-19 infection.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Beni-Suef University
• Collaborators: College of Pharmacy,Department of Pharmacy Practice,University of Arizona; Department of clinical pharmacy, faculty of pharmacy, Beni-suef univeristy; Maternity and Children Hospital, Makkah; University of Arizona
• Treatments: Quinine

Criteria

Inclusion Criteria:

• Symptomatic with respiratory or systemic symptoms

• Positive nasopharyngeal swab for COVID-19

• CT imaging showing viral pneumonia

• Temperature 38°C

• Respiratory rate < 25 /min

• Oxygen saturation (pulse oximetry) >95%

Exclusion Criteria:

• Pregnant or breast feeding

• Hepatic failure Child-Pugh C

• Negative swab test of (SARS)-(CoV-2)

• Expected life is less than 24 hours

• End-stage lung disease